Compound library
Understand what people are taking.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.
Polyphenol from grape skins and Japanese knotweed, famous for extending lifespan in yeast and mice. It has been tested in many human trials without convincing clinical benefit. Umbrella reviews rate its effects on blood sugar, cholesterol and blood pressure as trivial or very low certainty, and a meta-analysis of human brain and mood trials found the animal results are not replicated in people.
8 of 15 results reported a benefit, from 4 published studies.
4 studies, including a review of trials
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.
See every resultMemory, mental clarity, and overall brain health. Critical for healthy ageing and peak performance.
Also known as: trans-Resveratrol
Every published result for this pair, extracted and audited.
These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.
Direction of reported outcomes for Resveratrol in cognitive function.
Study designs behind these findings.
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Ginkgo biloba for cognitive impairment and dementiaWieland LS, et al. · The Cochrane database of systematic reviews · 2026PMID 41641880 ↗02Effects of acute exercise on cognitive function: A meta-review of 30 systematic reviews with meta-analysesChang YK, et al. · Psychological bulletin · 2025PMID 39883421 ↗03Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trialsRiepe M, et al. · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2025PMID 39895346 ↗04Associations between Diet and Cognitive Function in Stroke Survivors: A Systematic Review and Meta-analysisAmanat S, et al. · Advances in nutrition (Bethesda, Md.) · 2025PMID 40355028 ↗Be the first to share what you noticed with Resveratrol for cognitive function. Why counts start empty.
Every measured outcome, one row per finding - numbers exactly as reported.
| Study | Design | n | Duration | Outcome measured | Reported result | Direction |
|---|---|---|---|---|---|---|
| PMID 33303422 2021 | Meta-analysis | - | - | blood pressure | reported qualitatively | No benefit |
| PMID 33303422 2021 | Meta-analysis | - | - | cognitive assessments | reported qualitatively | No benefit |
| PMID 33303422 2021 | Meta-analysis | - | - | grey matter volume | reported qualitatively | No benefit |
| PMID 33303422 2021 | Meta-analysis | - | - | mood assessments | reported qualitatively | No benefit |
| PMID 29596658 2018 | Meta-analysis | 166 | - | delayed recognition | 0.39 (95% CI 0.08-0.70; I2 = 0%; P = 0.01) | Benefit |
| PMID 29596658 2018 | Meta-analysis | 163 | - | negative mood | -0.18 (95% CI -0.31 to -0.05; I2 = 0%; P = 0.006) | Benefit |
| PMID 32900519 2021 | Randomised trial | 125 | 24 months | CVR to cognitive stimuli | reported qualitatively (d = 0.259, P = 0.032) | Benefit |
| PMID 32900519 2021 | Randomised trial | 125 | 24 months | CVR to hypercapnia | reported qualitatively (d = 0.307, P = 0.027) | Benefit |
| PMID 32900519 2021 | Randomised trial | 125 | 24 months | Fasting insulin | reported qualitatively (d = 0.174, P = 0.025) | Benefit |
| PMID 32900519 2021 | Randomised trial | 125 | 24 months | Insulin resistance index | reported qualitatively (d = 0.102, P = 0.034) | Benefit |
| PMID 32900519 2021 | Randomised trial | 125 | 24 months | Overall cognitive performance | 33% (Cohen's d = 0.170, P = 0.005) | Benefit |
| PMID 32900519 2021 | Randomised trial | 125 | 24 months | Resting mean CBFV | reported qualitatively (d = 0.275, P = 0.001) | Benefit |
| PMID 26362286 2015 | Randomised trial | 119 | 52 weeks | Brain volume loss | reported qualitatively | Harm / risk |
| PMID 26362286 2015 | Randomised trial | 119 | 52 weeks | CSF Aβ40 levels | reported qualitatively | Unclear |
| PMID 26362286 2015 | Randomised trial | 119 | 52 weeks | plasma Aβ40 levels | reported qualitatively | Unclear |